CNS Pharmaceuticals, Inc. – NASDAQ:CNSP

Add to watchlist

$5.55

+5.43

+4815.85%

Market closed

Open in 2 days

-90.81%

month

-90.81%

quarter

-91.17%

year

Market Cap	6.12M
Enterprise value	N/A

P/E	-0.08
EV/Sales	N/A
EV/EBITDA	0.25
Price/Sales	N/A
Price/Book	0.11
PEG ratio	N/A
EPS	-3.48

Revenue	N/A
EBITDA	-17.45M
Income	-17.46M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Profit margin
Jun 2023	0	-4.02M
Sep 2023	0	-4.52M
Dec 2023	6.36K	-5.37M	-84489.94%
Mar 2024	0	-3.54M

CNS Pharmaceuticals Financials Estimate

Q Y

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Analyst Estimates
2027	83.98M	11.30M	13.46%

Analysts Price target
Financials & Ratios estimates

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Debt to assets
Jun 2023	6451604	3.99M	61.96%
Sep 2023	2328046	4.06M	174.77%
Dec 2023	1700853	6.13M	360.58%
Mar 2024	1660877	6.09M	366.76%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Cash Flow
Jun 2023	-3.40M	0	2.57M
Sep 2023	-3.37M	-1.74K	8.35K
Dec 2023	-2.53M	-2.15K	2.17M
Mar 2024	-3.19M	0	3.45M

CNS Pharmaceuticals alternative data

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Employee count
Aug 2023	3
Sep 2023	3
Oct 2023	3
Nov 2023	3
Dec 2023	3
Jan 2024	3
Feb 2024	3
Mar 2024	3
Apr 2024	3
May 2024	3
Jun 2024	3
Jul 2024	3

CNS Pharmaceuticals
Hedge Funds Holdings Q1 2023

3.88% -6.56%

of CNSP is owned by hedge funds

11 +2

hedge funds hold CNSP stock

52.84K -86.52K

shares is hold by hedge funds

CNSP hedge funds holdings changes

CNS Pharmaceuticals
Insider Trading

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): Insider trades (number of shares)
Period	Buy	Sel
Apr 2023	20600	0
Aug 2023	29750	0
Feb 2024	299998	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	1 Feb 2024	DOWNS CHRISTOPHER officer: Chief Financial Officer officer: Chief Financial Officer	Common stock	66,666	$0.3	$20,000
Purchase	1 Feb 2024	CLIMACO JOHN M director, officer..	Common stock	166,666	$0.3	$50,000
Purchase	1 Feb 2024	EVANS CARL ANTHONY director director	Common stock	33,333	$0.3	$10,000
Purchase	1 Feb 2024	GUMULKA JERZY director director	Common stock	33,333	$0.3	$10,000
Purchase	22 Aug 2023	DOWNS CHRISTOPHER officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	27,000	$1.27	$34,182
Purchase	16 Aug 2023	CLIMACO JOHN M director, officer..	Common Stock	2,750	$1.8	$4,945
Option	28 Apr 2023	CLIMACO JOHN M director, officer..	Common Stock	1,250	N/A	N/A
Option	28 Apr 2023	CLIMACO JOHN M director, officer..	Restricted Stock Units	1,250	N/A	N/A
Option	28 Apr 2023	DOWNS CHRISTOPHER officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	521	N/A	N/A
Option	28 Apr 2023	DOWNS CHRISTOPHER officer: Chief Financial Officer officer: Chief Financial Officer	Restricted Stock Units	521	N/A	N/A

CNSP insider trading transactions

CNS Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q4 2019 12 Mar 2020	Q4 2019 Earnings Call Transcript

CNSP earnings call transcripts

CNS Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. John Michael Climaco Esq., J.D. (1969) Chairman, Chief Executive Officer & Pres	56	$635,100
Mr. Christopher S. Downs CPA, CTP, FP&A (1979) Chief Financial Officer	46	$394,700
Dr. Sandra L. Silberman M.D., Ph.D. (1956) Chief Medical Officer	69	$213,900

CNS Pharmaceuticals
Latest News

Thursday, 5 December 2024
09:10	CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024	accesswire.com
Monday, 25 November 2024
09:00	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	accesswire.com
Monday, 18 November 2024
08:55	CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)	accesswire.com
Friday, 15 November 2024
09:10	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results	accesswire.com
Monday, 4 November 2024
09:15	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment	accesswire.com
Friday, 1 November 2024
09:00	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	accesswire.com
Wednesday, 23 October 2024
14:50	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules	accesswire.com
Thursday, 10 October 2024
09:00	CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment	accesswire.com
Tuesday, 8 October 2024
09:15	CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC	accesswire.com
Monday, 23 September 2024
09:00	CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum	accesswire.com
Thursday, 12 September 2024
09:00	CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement	accesswire.com
Wednesday, 4 September 2024
09:05	CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference	accesswire.com
Tuesday, 3 September 2024
08:00	IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.	globenewswire.com
Tuesday, 27 August 2024
09:10	CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	accesswire.com
Thursday, 22 August 2024
09:15	CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment	accesswire.com
Thursday, 15 August 2024
08:00	CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results	accesswire.com
Tuesday, 30 July 2024
12:03	Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?	investorplace.com
07:00	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies	accesswire.com
Thursday, 25 July 2024
09:05	CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference	accesswire.com
Tuesday, 16 July 2024
09:15	CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series	accesswire.com
Wednesday, 3 July 2024
11:10	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	accesswire.com
Wednesday, 26 June 2024
08:00	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	accesswire.com
Friday, 14 June 2024
15:11	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	accesswire.com
Monday, 3 June 2024
08:05	CNS Pharmaceuticals Announces Reverse Stock Split	accesswire.com
Monday, 20 May 2024
08:30	CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase	accesswire.com
Thursday, 16 May 2024
07:45	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results	accesswire.com
Tuesday, 23 April 2024
09:00	CNS Pharmaceuticals to Present at the LSX World Congress 2024	Accesswire
Monday, 1 April 2024
09:05	CNS Pharmaceuticals to Present at Two Investor Conferences in April	Accesswire
Friday, 9 February 2024
08:35	Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)	Benzinga
Tuesday, 5 September 2023
08:45	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference	Accesswire

Ideas & Opinions

Seeking Alpha 14 Jan 2024

Week In Review: China Biopharmas Book $9B In Deals During JP Morgan Conference Week

Frequently Asked Questions (FAQ)

What's the price of CNS Pharmaceuticals stock today?

One share of CNS Pharmaceuticals stock can currently be purchased for approximately $5.55.
When is CNS Pharmaceuticals's next earnings date?

Unfortunately, CNS Pharmaceuticals's (CNSP) next earnings date is currently unknown.
Does CNS Pharmaceuticals pay dividends?

No, CNS Pharmaceuticals does not pay dividends.
How much money does CNS Pharmaceuticals make?

CNS Pharmaceuticals has a market capitalization of 6.12M.
What is CNS Pharmaceuticals's stock symbol?

CNS Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CNSP".
What is CNS Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of CNS Pharmaceuticals?

Shares of CNS Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are CNS Pharmaceuticals's key executives?
CNS Pharmaceuticals's management team includes the following people:
- Mr. John Michael Climaco Esq., J.D. Chairman, Chief Executive Officer & Pres(age: 56, pay: $635,100)
- Mr. Christopher S. Downs CPA, CTP, FP&A Chief Financial Officer(age: 46, pay: $394,700)
- Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer(age: 69, pay: $213,900)
How many employees does CNS Pharmaceuticals have?

As Jul 2024, CNS Pharmaceuticals employs 3 workers.
When CNS Pharmaceuticals went public?

CNS Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 8 Nov 2019.
What is CNS Pharmaceuticals's official website?

The official website for CNS Pharmaceuticals is cnspharma.com.
Where are CNS Pharmaceuticals's headquarters?

CNS Pharmaceuticals is headquartered at 2100 West Loop South, Houston, TX.
How can i contact CNS Pharmaceuticals?

CNS Pharmaceuticals's mailing address is 2100 West Loop South, Houston, TX and company can be reached via phone at +800 9469185.

CNS Pharmaceuticals, Inc.

cnspharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

+800 9469185

2100 West Loop South
Houston, TX 77027

CIK: 0001729427
ISIN: US18978H2013
CUSIP: 18978H102